<DOC>
	<DOCNO>NCT02470065</DOCNO>
	<brief_summary>This multicenter , randomize , 1:1 , non-comparative phase II trial . Patients early stage NSCLC randomize ARM A : neoadjuvant afatinib follow surgery ARM B : immediate surgery curative intent .</brief_summary>
	<brief_title>Neoadjuvant Afatinib Early Stage Non Small Cell Lung Cancer .</brief_title>
	<detailed_description>This multicenter , prospective , open-label , randomize , non-comparative , two-arm phase II trial aim evaluate afatinib treatment pre-operative setting patient EGFR mutate NSCLC . After sign informed consent , patient register screened eligibility upon confirmation eligibility criterion , patient randomize 1:1 : - Arm A : daily afatinib dose 40 mg 8 week follow surgery curative intent ( anatomical resection systematic lymph node dissection ) . - Arm B : immediate surgery curative intent ( anatomical resection systematic lymph node dissection ) . Response evaluation pre-operative arm perform CT scan baseline , 4 8 week . The first 5 patient enrol arm A part safety run-in check afatinib treatment n't delay surgery .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological diagnosis NSCLC ; Patients consider operable resectable tumor curative intent ( anatomical resection systematic lymph node dissection ) base evaluation thoracic multidisciplinary team compose least thoracic surgeon , oncologist radiologist ; Stage IIII ( T1a3 , N01 , M0 accord UICC version 7 ) NSCLC local stag criterion potentially treatable radical ( curative ) surgery . Patients T1 tumor baseline limit 20 % ; Radiologically measurable disease accord RECIST criterion 1.1 ; assess chest upper abdomen CT scan within 2 week ( +1 week ) prior registration ) ; brain CT scan MRI accord local practice ; No prior treatment NSCLC allow ; Adequate tissue term quality quantity EGFR local testing . adequate bone marrow function within 2 week prior randomization adequate liver function . Patients Gilbert 's syndrome total bilirubin must 4 time institutional upper limit normal ; within 2 week prior randomization adequate renal function within 2 week prior randomization know positivity human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C ; know history allergic reaction attribute compound similar chemical biological composition ; history hematologic primary solid tumor malignancy , unless evidence disease 5 year , except pT12 prostatic cancer Gleason score &lt; 6 , superficial bladder cancer , non melanoma skin cancer carcinoma situ cervix ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Early stage</keyword>
	<keyword>Phase II</keyword>
	<keyword>Randomized</keyword>
	<keyword>EGFR mutate</keyword>
</DOC>